Phase I, double-blind, placebo-controlled study of safety, tolerability and short-term efficacy of LY2409021 in patients with type 2 diabetes mellitus treated with diet and exercise or metformin.

Trial Profile

Phase I, double-blind, placebo-controlled study of safety, tolerability and short-term efficacy of LY2409021 in patients with type 2 diabetes mellitus treated with diet and exercise or metformin.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2015

At a glance

  • Drugs Adomeglivant (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 May 2012 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
    • 23 May 2012 Actual initiation date (March 2008) and trial locations added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top